Thrombogenics

Thrombogenics N.V.
Stock Exchange Other OTC
EPS
$1.18
Market Cap
$192.8 M
Shares Outstanding
38.27 M
Public Float
-

Profile

Address
Gaston Geenslaan 1
Leuven VL 3001
Belgium
Employees -
Website http://www.oxurion.com
Updated 07/08/2019
ThromboGenics NV is a biopharmaceutical company, which engages in developing and commercializing medicines for the treatment of vitreo retinal diseases. It operates under JETREA (ocriplasmin) brand name. The company was founded by Desire Collen in 1991 and is headquartered in Leuven, Belgium.

Financials

View All

Patrik de Haes
Chief Executive Officer & Executive Director
Paul G. Howes
Non-Executive Director